Research and Markets: iPS Cells Differentiation patent landscape (2013-03)

Research and Markets: iPS Cells Differentiation patent landscape (2013-03)

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

Many diseases such as cardiovascular disorders, diabetes or neurodegenerative diseases are the consequences of dysfunction of specific cells. Strategies were developed to repair or regenerate the damaged tissues using differentiated cells out of stem cells. However, ethical and scientific issues are related to the use of embryonic stem cells. In this context, induced pluripotent stem cells (iPS) appear as a promising approach. The patient's somatic cells are first dedifferentiated into iPS cells and then redifferentiated into the cell of interest.

This revolutionary technology represents major scientific, societal and economic challenges and was recently rewarded by a Nobel Prize in Physiology and Medicine to Prof. Shinya Yamanaka and Prof. John Gurdon.

With over 1000 patent families qualified and analyzed out of a pool of 3000 patent families, we have analysed:

- The iPS cells generation patent landscape

The analysis of this patent landscape shows a strong complexity of the environment and demonstrates the ability of institutional players to develop a consistent IP strategy like the one from Kyoto university. Some major players already present in 2011 increased sharply their filings: the Kyoto university, the Chinese Academy of Sciences, the laboratories of US government. New entrants have filed numerous patent applications in the last years: Korea university, AIST, Cellular Dynamics, Salk Institute and A*STAR (SG).

- The iPS cells differentiation patent landscape

As for the thematic iPS cells generation, the main players are mainly institutional (23 institutional applicants in the top 30) with the university of Kyoto and the laboratories of the US government at the first two places. However, industrial applicants from all over the world clearly positioned themselves on the thematic such as Cellular Dynamics (US),

Cellectis (FR) or Viacyte (US).

The technological breakdowns presented in this study had shown specific positioning of the players through their patent applications notably regarding the type of cell obtained from the differentiation of iPS cells. Cardiovascular, neural, pancreatic cells are the most claimed by the applicants, this corresponding to the main pathologies observed nowadays. Hepatic cells are also often claimed notably for the establishment of toxicology studies.

- The iPS cells database

Additionally, all patents dealing with iPS cells but who were concerning neither generation nor differentiation (thus all patents related to culture, selection, isolation, etc) were grouped together in a database to get a full overview of the iPS landscape.

REASONS TO BUY:

These patent landscapes provide you a comprehensive panorama of the intellectual property overview and help you:

- Identify key inventors and players involved in the generation and differentiation of iPS cells

- Understand their positioning, the collaboration networks and their dynamics

- Analyze their IP strategy

- Position your company's R&D and IP portfolio·

- Discover new trends and emerging topics

A three months access to the corresponding patent database, dynamic and interactive, is also included.

For more information visit

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.